Irish Pharma Manufacturers Eye US Sites to Outrun Tariff Risk

Cork-based pharmaceutical manufacturers are moving to establish US-based operations as concerns mount over the cost impact of importing drugs from Irish facilities into the American market. The shift signals a structural recalibration of supply chain strategy for indigenous Irish pharma companies, with direct consequences for site selection, regulatory site transfers, and the long-term viability of Irish manufacturing capacity.

The tariff pressure is forcing companies to weigh the cost and complexity of standing up US manufacturing sites against the risk of losing market access or price competitiveness. For plant heads and QA directors, this means potential regulatory site transfers under FDA oversight, requiring updated process validation packages, site-specific GMP compliance assessments under 21 CFR Part 211, and alignment with ICH Q10 pharmaceutical quality system requirements across dual-site operations.

The strategic calculus is not straightforward. Establishing a compliant US manufacturing presence demands significant capital investment, qualified personnel, and a regulatory pathway that can take years to execute. Companies must also manage the continuity of supply from existing Irish sites during any transition, maintaining sterility assurance levels and batch release standards without interruption to patient supply chains.

For regulatory affairs leads, the immediate priority is assessing whether existing product registrations can accommodate a site transfer or whether full supplemental submissions to FDA will be required. The scope of comparability and validation data needed will depend on dosage form, product complexity, and the manufacturing steps being relocated.

Source: This article is based on reporting by Pharmaceutical Industry News, published 26 April 2026, citing statements from Cork-based indigenous pharmaceutical manufacturing companies regarding tariff concerns and US market access.